Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

NCT02184767 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.